Medicxi Ventures Management (Jersey) Ltd — 13F Holdings & Portfolio

CIK 1715579 · latest 13F-HR filed 2026-08-04

Medicxi Ventures Management (Jersey) Ltd manages $177.4M in 13F-reported U.S. long-equity assets across 3 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are PHAT (45.65%), NAMS (42.19%), AURA (12.16%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 0 new positions, exited 1, added to 1, and trimmed 1.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Filer Information
Address
C/O CSC FUND SERVICES (JERSEY) LIMITED
44 ESPLANADE
ST. HELIER, Y9 JE4 9WG
Phone
44 (0) 1534 504343
Filing Manager
Medicxi Ventures Management (Jersey) Ltd
ST. HELIER, Y9
Signatory
Giles Johnstone-Scott
Director
Loading holdings…
AUM

$177.4M

Long-equity book

Holdings

3

Distinct positions

Period

2026-06-30

Filed 2026-08-04

Q/Q Activity

+0 / −1 / ↑1 / ↓1

vs 2026-03-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • AURA BIOSCIENCES INC$1.2M +6.1%
Show all 1

Top Trims

  • NEWAMSTERDAM PHARMA COMPANY-$10.7M -12.6%
Show all 1

New Positions

  • No new positions this quarter.
Show all 0

Exited Positions

  • CENTESSA PHARMACEUTICALS PLC$792.9M
Show all 1
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 PHATHOM PHARMACEUTICALS INC PHAT 71722W107 $81.0M 45.65% 7,464,572 SH
2 NEWAMSTERDAM PHARMA COMPANY NAMS N62509109 $74.9M 42.19% 2,208,639 SH
3 AURA BIOSCIENCES INC AURA 05153U107 $21.6M 12.16% 3,039,892 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-04 $177.4M 3 0001193125-26-332000
2026-03-31 2026-04-21 $981.8M 4 0001193125-26-166701
2025-12-31 2026-01-23 $835.0M 5 0001193125-26-020931